Compass’ range

How Compass’ technology generates large multispecific libraries

Compass Therapeutics LLC combines human cell display, high throughput antibody screening and a multispecific engineering platform to develop large libraries of cancer and autoimmune therapies.

Traditional approaches to antibody discovery use hybridoma fusions in animals, phage display or yeast cell surface display, followed by a humanizing step, which co-founder and CEO Thomas Schuetz said generates smaller libraries of antibodies with less epitopic diversity than Compass’ approach.

Compass

Read the full 662 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE